Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:35 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,349 matching trials from the live ClinicalTrials.gov search.
Filters: New Haven, Connecticut Clear all
Completed No phase listed Observational

Deceased Donor Biomarkers and Recipient Outcomes

NCT01848249
View directory record Official record
Conditions
Deceased Donor Kidney Transplant, Acute Kidney Injury, Delayed Graft Function, End Stage Renal Disease, Graft Failure
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
1,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
17
States / cities
New Haven, Connecticut • Baltimore, Maryland • Waltham, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Nov 3, 2026, 4:35 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Digital Intervention to Prevent the Initiation of Opioid Misuse in Adolescents in School-based Health Centers

NCT04941950
View directory record Official record
Conditions
Opioid Misuse
Interventions
PlaySmart, Video Game Control
Behavioral · Other
Lead sponsor
Tyra Boomer
Other
Eligibility
16 Years to 19 Years
Enrollment
533 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
15
States / cities
Bridgeport, Connecticut • Durham, Connecticut • East Hartford, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 3, 2026, 4:35 AM EST
Completed Not applicable Interventional Results available

Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

NCT03241459
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Vascular Disease, Artery Disease, Peripheral, Femoropopliteal Artery Occlusion
Interventions
Surmodics SurVeil DCB, Medtronic IN.PACT Admiral DCB
Device
Lead sponsor
SurModics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
50
States / cities
Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Nov 3, 2026, 4:35 AM EST
Completed Phase 2 Interventional Results available

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis

NCT05080660
View directory record Official record
Conditions
Osteoarthritis, Osteo Arthritis Knee
Interventions
LY3526318, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
Chandler, Arizona • Glendale, Arizona • Tempe, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Nov 3, 2026, 4:35 AM EST
Active, not recruiting No phase listed Observational

PRISM: Patient Experiences With PET Imaging in Prostate Cancer

NCT06523777
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Bridgeport, Connecticut • Derby, Connecticut • Greenwich, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 3, 2026, 4:35 AM EST
Recruiting No phase listed Observational

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

NCT05907629
View directory record Official record
Conditions
Stroke, Intracranial Atherosclerotic Stenosis (ICAS)
Interventions
MRI
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
28
States / cities
Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 3, 2026, 4:35 AM EST
Active, not recruiting Not applicable Interventional

SELUTION 4 De Novo Small Vessel IDE Trial

NCT05946629
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
Device
Lead sponsor
M.A. Med Alliance S.A.
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
65
States / cities
Jonesboro, Arkansas • Chula Vista, California • Los Angeles, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 3, 2026, 4:35 AM EST
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

NCT03224351
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659, TEZ/IVA, IVA, Placebo (matched to VX-659/TEZ/IVA), TEZ, VX-561, Placebo (matched to VX-659/TEZ/VX-561)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
25
States / cities
New Haven, Connecticut • Miami, Florida • Morton Grove, Illinois + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Nov 3, 2026, 4:35 AM EST
Completed Not applicable Interventional

Short Term Effects of Electronic Cigarettes in Tobacco Dependent Adults

NCT02498145
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Nicotine e-cigarette, Non-nicotine e-cigarette
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 3, 2026, 4:35 AM EST
Recruiting Phase 3 Interventional

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Interventions
Vepugratinib, Placebo, EV, Pembrolizumab
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
64
States / cities
Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 3, 2026, 4:35 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Group Prenatal Care for Reducing the Risk of STDs in Pregnant Young Women

NCT00271960
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
CenteringPregnancy, CenteringPregnancyPlus, Usual care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
14 Years to 25 Years · Female only
Enrollment
1,047 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
2
States / cities
New Haven, Connecticut • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Nov 3, 2026, 4:35 AM EST
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347

NCT03275740
View directory record Official record
Conditions
Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Nov 3, 2026, 4:35 AM EST
Completed No phase listed Observational

FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study

NCT00288613
View directory record Official record
Conditions
Kidney Failure, Chronic, End Stage Renal Disease, Requiring Dialysis
Interventions
Not listed
Lead sponsor
NxStage Medical
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
41
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Garden Grove, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Nov 3, 2026, 4:35 AM EST
Completed Phase 2 Interventional

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

NCT01204762
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
pegIFN, pegIFNα-2a, PegIFN lambda, Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Anaheim, California • Garden Grove, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Nov 3, 2026, 4:35 AM EST
Terminated Phase 3 Interventional Results available

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

NCT02718417
View directory record Official record
Conditions
Ovarian Cancer
Interventions
carboplatin, paclitaxel, Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
146
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Nov 3, 2026, 4:35 AM EST
Active, not recruiting Phase 3 Interventional

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

NCT06211036
View directory record Official record
Conditions
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Interventions
Tarlatamab, Durvalumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
37
States / cities
Mobile, Alabama • Los Angeles, California • New Haven, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 3, 2026, 4:35 AM EST
Recruiting Not applicable Interventional

Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid Regurgitation

NCT07321899
View directory record Official record
Conditions
Severe Tricuspid Regurgitation
Interventions
Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System, Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
1,186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Thousand Oaks, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 4:35 AM EST
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

NCT01363947
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Ovarian Cancer
Interventions
DNIB0600A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Nov 3, 2026, 4:35 AM EST
Completed Not applicable Interventional

Study of an App to Facilitate Communication With Parents of Febrile Infants

NCT04328909
View directory record Official record
Conditions
Fever
Interventions
E-Care, Control Group
Device · Other
Lead sponsor
Yale University
Other
Eligibility
1 Day to 60 Days
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Nov 3, 2026, 4:35 AM EST
Terminated Phase 1 Interventional Results available

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

NCT02669264
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
ADCT-402
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
12 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
La Jolla, California • New Haven, Connecticut • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Nov 3, 2026, 4:35 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)

NCT04856293
View directory record Official record
Conditions
Healthy Participants
Interventions
Crizotinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Nov 3, 2026, 4:35 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants

NCT05263921
View directory record Official record
Conditions
Bioavailability
Interventions
PF-07321332/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Nov 3, 2026, 4:35 AM EST
Not yet recruiting No phase listed Observational

REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness

NCT07792252
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Rejoyn, Cognitive Behavioral Therapy (CBT) exercises
Device · Behavioral
Lead sponsor
Yale University
Other
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Greenwich, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Nov 3, 2026, 4:35 AM EST
Terminated Phase 1 Interventional Results available

A Study of LY3405105 in Participants With Advanced Cancer

NCT03770494
View directory record Official record
Conditions
Solid Tumor
Interventions
LY3405105
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Fayetteville, Arkansas • New Haven, Connecticut • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 3, 2026, 4:35 AM EST